ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Ayala Pharmaceuticals Inc (CE)

Ayala Pharmaceuticals Inc (CE) (ADXS)

0.027
0.00
( 0.00% )
Updated: 18:00:00

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.027
Bid
0.00
Ask
0.00
Volume
591
0.027 Day's Range 0.027
0.0012 52 Week Range 1.49
Market Cap
Previous Close
0.027
Open
0.027
Last Trade
40
@
0.027
Last Trade Time
10:21:13
Financial Volume
US$ 16
VWAP
0.027
Average Volume (3m)
2,718
Shares Outstanding
42,633,400
Dividend Yield
-
PE Ratio
-0.03
Earnings Per Share (EPS)
-1.13
Revenue
13k
Net Profit
-48.07M

About Ayala Pharmaceuticals Inc (CE)

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer ... Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma (ACC), T-cell Acute Lymphoblastic Leukemia (T-ALL), and Desmoid Tumors. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Ayala Pharmaceuticals Inc (CE) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker ADXS. The last closing price for Ayala Pharmaceuticals (CE) was US$0.03. Over the last year, Ayala Pharmaceuticals (CE) shares have traded in a share price range of US$ 0.0012 to US$ 1.49.

Ayala Pharmaceuticals (CE) currently has 42,633,400 shares outstanding. The market capitalization of Ayala Pharmaceuticals (CE) is US$1.15 million. Ayala Pharmaceuticals (CE) has a price to earnings ratio (PE ratio) of -0.03.

ADXS Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1000.0270.10510.0277940.027CS
4000.0270.10510.02637640.04647757CS
12-0.06305-70.01665741250.090050.10510.02627180.04358426CS
26-0.213-88.750.240.2870.001234570.10941927CS
52-0.603-95.71428571430.631.490.0012117090.69518545CS
156-0.163-85.78947368420.194.50.00121381070.17308792CS
260-0.108-800.1354.990.00121538440.17601348CS

ADXS - Frequently Asked Questions (FAQ)

What is the current Ayala Pharmaceuticals (CE) share price?
The current share price of Ayala Pharmaceuticals (CE) is US$ 0.027
How many Ayala Pharmaceuticals (CE) shares are in issue?
Ayala Pharmaceuticals (CE) has 42,633,400 shares in issue
What is the market cap of Ayala Pharmaceuticals (CE)?
The market capitalisation of Ayala Pharmaceuticals (CE) is USD 1.15M
What is the 1 year trading range for Ayala Pharmaceuticals (CE) share price?
Ayala Pharmaceuticals (CE) has traded in the range of US$ 0.0012 to US$ 1.49 during the past year
What is the PE ratio of Ayala Pharmaceuticals (CE)?
The price to earnings ratio of Ayala Pharmaceuticals (CE) is -0.03
What is the cash to sales ratio of Ayala Pharmaceuticals (CE)?
The cash to sales ratio of Ayala Pharmaceuticals (CE) is 100
What is the reporting currency for Ayala Pharmaceuticals (CE)?
Ayala Pharmaceuticals (CE) reports financial results in USD
What is the latest annual turnover for Ayala Pharmaceuticals (CE)?
The latest annual turnover of Ayala Pharmaceuticals (CE) is USD 13k
What is the latest annual profit for Ayala Pharmaceuticals (CE)?
The latest annual profit of Ayala Pharmaceuticals (CE) is USD -48.07M
What is the registered address of Ayala Pharmaceuticals (CE)?
The registered address for Ayala Pharmaceuticals (CE) is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the Ayala Pharmaceuticals (CE) website address?
The website address for Ayala Pharmaceuticals (CE) is www.ayalapharma.com
Which industry sector does Ayala Pharmaceuticals (CE) operate in?
Ayala Pharmaceuticals (CE) operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RAASYCloopen Group Holding Limited (CE)
US$ 0.05
(4,999,900.00%)
222
ELIQQElectriq Power Holdings Inc (CE)
US$ 0.10
(99,900.00%)
100
HAVLFHavn Life Sciences Inc (CE)
US$ 0.001
(99,900.00%)
15.12k
STTOSITO Mobile Ltd (CE)
US$ 0.0012
(59,900.00%)
500
LTFDLittlefield Corporation (CE)
US$ 0.11
(36,566.67%)
1.8k
NOKPFNok Airlines Public Company Ltd (CE)
US$ 0.0001
(-99.75%)
157.79k
NEOMNeoMedia Technologies Inc (CE)
US$ 0.000001
(-99.50%)
50.34k
IFANIFAN Financial Inc (CE)
US$ 0.000001
(-99.50%)
114k
AMINAmerican International Industries Inc (CE)
US$ 0.0001
(-99.50%)
1,000
MAPTMAPtelligent Inc (CE)
US$ 0.000001
(-99.00%)
165k
PHILPHI Group Inc (PK)
US$ 0.0005
(66.67%)
315.7M
HMBLHUMBL Inc (PK)
US$ 0.0008
(0.00%)
165.47M
RDARRaadr Inc (PK)
US$ 0.0015
(11.11%)
107.87M
GRLFGreen Leaf Innovations Inc (PK)
US$ 0.0001
(0.00%)
79.22M
AITXArtificial Intelligence Technology Solutions Inc (PK)
US$ 0.0026
(-3.70%)
43.46M

ADXS Discussion

View Posts
willlbone willlbone 8 months ago
Form 15, to de-register.
πŸ‘οΈ0
James salmon James salmon 10 months ago
Sorry I keep putting IMNU I mean IMNM
πŸ‘οΈ0
James salmon James salmon 10 months ago
Well IMNU holding just hit $60 million or there abouts.
πŸ‘οΈ0
James salmon James salmon 10 months ago
Actually make that $50 million at todays IMNU price
πŸ‘οΈ0
James salmon James salmon 10 months ago
Agree they hold over well $40 million in IMNU stock
πŸ‘οΈ0
willlbone willlbone 10 months ago
Under 70 cent is a bargain.
πŸ‘οΈ0
ignatiusrielly35 ignatiusrielly35 11 months ago
Aye aye. Good luck with it.
πŸ‘οΈ0
James salmon James salmon 11 months ago
Looking at filing I think the deal will close very quickly as most of the shares are held by a few investors or funds, I see Feb 8th mentioned in the filing for funds to approve.
πŸ‘οΈ0
ignatiusrielly35 ignatiusrielly35 11 months ago
Well the market obviously likes the deal.
πŸ‘οΈ0
James salmon James salmon 11 months ago
I wish it was mine but talking about the increase ADXS has seen in its holding of IMNU stock, when deal goes through.
πŸ‘οΈ0
ignatiusrielly35 ignatiusrielly35 11 months ago
Nice work, James.
πŸ‘οΈ0
James salmon James salmon 11 months ago
Well IMNU just hit $25, so that $30 million just became $54 million on paper in stock.
πŸ‘οΈ0
ANTI-BAGHOLDER ANTI-BAGHOLDER 11 months ago
Only 3 milly floater too. :)
πŸ‘οΈ0
Bigstud is here Bigstud is here 11 months ago
What price did u bought them at?
πŸ‘οΈ0
James salmon James salmon 11 months ago
I just noticed the actual amount of shares ADXS will get, it’s 2,175,489 shares which at $22 a share which is IMNU current share price that is $48 million.

ADXS got the shares at $13.79 in this deal disclosed today.

Add the $20 million in cash and $37 million in milestones.

ADXS current market cap is just under $15 million.

For the first time in a longtime I can say ADXS is cheap, very cheap.
πŸ‘οΈ0
James salmon James salmon 11 months ago
Well snagged a few thousand at open, no brainer with news this morning.
πŸ‘οΈ0
James salmon James salmon 11 months ago
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile


BOTHELL, Wash. and MONMOUTH JUNCTION, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, to acquire AL102 and related drug candidate AL101 from Ayala. Based on the terms of the agreement, Immunome will pay Ayala $20 million in cash and $30 million in Immunome common stock (valued at 30-day VWAP as of February 1, 2024) at the closing and will pay up to an additional $37.5 million in development and commercial milestone payments. Completion of the transaction is subject to customary conditions including Ayala obtaining the requisite stockholder approval.
πŸ‘οΈ0
AJ Freely AJ Freely 1 year ago
$ADXS - Ayala Pharmaceuticals to Merge w/ Biosight Ltd, a privately-held pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders
To close prior to Q3 23
Float under 5 m
πŸ‘οΈ0
AJ Freely AJ Freely 1 year ago
$ADXS - Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Merger to add a clinical stage oncology asset to Ayala’s portfolio with data anticipated in the H1 '24
πŸ‘οΈ0
AJ Freely AJ Freely 1 year ago
$ADXS - Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Merger to add a clinical stage oncology asset to Ayala’s portfolio with data anticipated in the H1 '24
πŸ‘οΈ0
island man island man 1 year ago
Hi GF
Check Qbts And Rxrx could move soon
πŸ‘οΈ0
island man island man 1 year ago
Hi GF
Into Qbts and some bzfd with a sprinkle of Rxrx could be riding a wave 🍾🍾👍👍
πŸ‘οΈ0
Renee Renee 2 years ago
Advaxis Inc. changed to Ayala Pharmaceuticals Inc.

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
πŸ‘οΈ0
James salmon James salmon 2 years ago
ASCO abstract highlights 50% partial response and 100% disease control rates in evaluable desmoid tumor patients treated with AL102 1.2 mg once daily (the selected Phase 3 dose)

Tumor response, volume and T2 signal reduction were observed earlier in the 1.2 mg once daily group, with deeper and sustained treatment responses

Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally.

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced updated results from Phase 2 (Part A segment) of the RINGSIDE study evaluating AL102 in desmoid tumors. The results are summarized in an abstract published today for the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. More detailed results will be featured in a poster session at ASCO on Saturday, June 3. AL102 is a once-daily, potent, selective, oral gamma-secretase inhibitor (GSI).
πŸ‘οΈ0
hdwrsft hdwrsft 2 years ago
The only safe haven for $$$$ these days seems to be under the mattress.
πŸ‘οΈ0
Ryguy008 Ryguy008 2 years ago
What a turd. CEO Ken is running this into the ground with his carelessness.

$ADXS
πŸ‘οΈ0
hdwrsft hdwrsft 2 years ago
Another massive bank shockingly failed. One day it's biz as usual, the next day, total implosion. Banking customers freaking the fvck out.

Omg. Geez. I know how that feels...like right after that first massive R/S. At that point, subsequent R/S further obliterated what little was left.

Expensive lesson of the game for sure. All the wiser.

The banking news this week makes the losses suffered over the many years in this next of the woods look like shriveled mouse nuts.




πŸ‘οΈ0
hdwrsft hdwrsft 2 years ago
Just think, in just another 7 years, and who knows how many more R/S between now and then, this biz will have somehow survived, what???

Will it be THREE DECADES???

OMG.

Enuff said....

πŸ‘οΈ0
HereToFightScams HereToFightScams 2 years ago
If there is any justice in this universe, both Ken the sleasebag lawyer and Sidransky the supposed doctor with no patients and primary allegiance to his Israeli hedge fund companies, will spend the next decade or so in prison to account for their sins.
πŸ‘οΈ0
carp77 carp77 2 years ago
Looks like things are picking up we may surpass 1000 bucks in total trades today
πŸ‘οΈ0
James salmon James salmon 2 years ago
Well it’s certainly been a learning experience. I would not say broke as I sold enough on the run to $30 to cover my initial investment and some. I left a lot on the table and could have been set up nicely if I had sold all.

I have made some up on other stocks and one thing I learned was to spread the money around and not be over invested in 1 stock.
πŸ‘οΈ0
oakrock oakrock 2 years ago
James, Are you as broke as I am from ADXS?
πŸ‘οΈ0
hdwrsft hdwrsft 2 years ago
Hmm (Glancing at the EOY PPS).

Some things never change.

πŸ‘οΈ0
hdwrsft hdwrsft 2 years ago
Them pesty R/S's pop up quicker than weeds at springtime in these parts.
πŸ‘οΈ0
ADXSINC ADXSINC 2 years ago
Waiting patiently for the next 20 for 1 reverse split.......
πŸ‘οΈ0
hdwrsft hdwrsft 2 years ago
Crickets.
πŸ‘οΈ0
Traderbx Traderbx 2 years ago
I see alot of same names (fellow bag holders) still posting here… anyone recovered their ADXS losses from elsewhere yet?
πŸ‘οΈ0
hdwrsft hdwrsft 2 years ago
The last of someones FTX crypto currency investdonation......?
πŸ‘οΈ0
girlfriend girlfriend 2 years ago
Salmon man adding?
πŸ‘οΈ0
ADXSINC ADXSINC 2 years ago
That was blue eyes, she is still buying
πŸ‘οΈ0
hdwrsft hdwrsft 2 years ago
Volume posted this early AM:

"1"


Totally laughable.
πŸ‘οΈ0
ubmmg ubmmg 2 years ago
Not sure what data you are referring to. Is it this:"ADXS-503: Phase 1/2 combination with KEYTRUDA updated clinical and immune/biomarker data for KEYTRUDA failures and initial readout in first-line patients"? Haven't been following this POS for some time...
πŸ‘οΈ0
phytokaiser1 phytokaiser1 2 years ago
Hi Nick,

So my Ph.D. is in plant biology (breeding and natural products), but I actually worked in a medicinal chemistry lab modifying natural products for improved pharmacological function. I own multiple patents on plants that have improved phenotypic characteristics.

I bring this up, because I know a lot about fungi and psilocybin. Personally, I think Lions Mane is the most valuable fungi due to its neuroregenerative properties. However, psilocybin seems to be incredibly promising in addiction and end of life care. I haven't looked at the landscape, but I know Peter Thiel backed this pharma company.

https://atai.life/

They are on a huge hiring spree at the moment for senior level members.

https://boards.greenhouse.io/atai
πŸ‘οΈ0
Nickwvt Nickwvt 2 years ago
I'm hearing a lot of chatter about psylocybin mushrooms being used for medicinal purposes. Don't know if that fits into your area of expertise or not.....just throwing it out there
πŸ‘οΈ0
phytokaiser1 phytokaiser1 2 years ago
Thanks man, much appreciated. Good luck and stay safe.
πŸ‘οΈ0
ignatiusrielly35 ignatiusrielly35 2 years ago
Don’t give up, Phyto. Network, and talk to as many people as possible. You never know where an idea may come from. All of my best to you.
πŸ‘οΈ0
phytokaiser1 phytokaiser1 2 years ago
Thanks and ya, it has been difficult but thanks for your thoughts. I have been looking at head hunters but they have told me multiple times that they do not utilize scientists in the way I want to work lol. But I will keep trying.

Good news on AVXL, thanks for the heads up years ago!
πŸ‘οΈ0
ignatiusrielly35 ignatiusrielly35 2 years ago
Gee, I’m not sure on that one, phyto. Nothing immediately comes to mind as to investment firms that might need expertise in plant biology to analyze investments. If it was biochemistry, different story, obviously. I’m not even sure if commodities outfits use plant biologists to analyze crop supply, such as wheat FCOJ, etc. Maybe you should research some headhunters who specialize in financial analysts. Clearly they would want you for your scientific knowledge and not as an actual financial analyst.

Congrats on your PhD! Big achievement!
πŸ‘οΈ0
phytokaiser1 phytokaiser1 2 years ago
Hey!

It's good to talk to you again. I kind of took a break from stocks and investing over the past few years. Got my PhD (Finally) and went to work. The crash of ONVO and ADXS sucked so I was watching stocks from a distance (Though I made a little on AMC lol).

I actually wanted to pick your brain a little and ask for some advice. I got a PhD in plant biology and was wondering how I could enter the financial markets with this since I don't have a lot of formal training in the sector. It is definitely something I am interested in but am having trouble breaking in/getting interviews.

Good talking to you again, let me know if you want me to review any technical aspects for anything, feels good to be back on the boards.
πŸ‘οΈ0
ignatiusrielly35 ignatiusrielly35 2 years ago
If the data are good it will hit resistance at 40. My prediction and I’m sticking with it. They’ll allow it to that point as an inflection, then the takedown. Is there any logic involved? No. They don’t need logic.

It’s a guess.

Data bad? Unlikely. But if it’s mixed they will still allow it to hit 40, then they will take it down.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock